First clinical trials of malaria vaccine suggest it could help fight the disease and prevent millions of cases of the deadly disease every year. The findings reveal that vaccine efficacy against clinical and severe malaria was better in children than in young infants, but waned over time in both groups. The results suggested that the vaccine could prevent a substantial number of cases of clinical malaria, especially in areas of high transmission.
- The RTS,S/AS01 vaccine was developed for use in sub-Saharan Africa where malaria still kills around 1300 children every day.
- However, protection was prolonged by a booster dose, increasing the average number of cases prevented in both children and young infants.
- There is currently no licensed vaccine against malaria anywhere in the world.